Yutao Liu from Georgia Regents University: Delaying the Progression of Glaucoma

Video

Yutao Liu, MD, PhD, Georgia Regents University, discussed how he and his team can potentially target genes to either reduce glaucoma or provide neuroprotection specifically for the mitochondria in the retina.

At the ARVO 2016 meeting in Seattle, WA, Yutao Liu, MD, PhD, Georgia Regents University, discussed how he and his team can potentially target genes to either reduce glaucoma or provide neuroprotection specifically for the mitochondria in the retina.

Liu concluded, "One thing I want to emphasize is eye disease is a very severe disease. Especially for glaucoma, the main thing is that in the clinic, most people are not aware of the glaucoma they have because it's a painless disease. So, we recommend people over the age of 40 to go see a clinician in opthalmology to do an eye exam to serve as the baseline, since glaucoma depends on progression."

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.